To include your compound in the COVID-19 Resource Center, submit it here.

Fourth-line GIST showdown ends in an FDA win for Deciphera, a rejection for Blueprint

Blueprint drug denied in the same indication, and Clovis’ PARP inhibitor gains approval in prostate cancer

FDA approved Qinlock repretinib from Deciphera as fourth-line treatment for advanced gastrointestinal stromal tumors (GIST), marking the first approved therapy for the indication.

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE